Oct 14, 2026
THEY SAID IT! R STREET CALLS FOR BIPARTISAN, MARKET-BASED SOLUTIONS TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE
Article Highlights How Congress Can Address Patent Thickets, Product Hopping And Other…
© 2026 CSRXP- All Rights Reserved
HOLDING BIG PHARMA ACCOUNTABLE
HOLDING
BIG PHARMA ACCOUNTABLE
CSRxP advocates for bipartisan solutions that hold pharmaceutical companies accountable for egregious pricing and anti-competitive practices that are the root cause of out-of-control drug prices in America.
We believe in market-based reforms to lower drug prices for patients through increased transparency, competition and value.
Big Pharma thinks it’s a master of disguise… But it can’t disguise the truth.
The BIG PHARMA Playbook
Big Pharma’s business-as-usual playbook relies on egregious pricing practices and rhetoric designed to set and keep drug prices high.
Out-of-Control Price Hikes & Launch Prices
Innovation Rhetoric Disconnected from the Facts
Blame Game Designed to Keep Prices High
Anti-Competitive Tactics & Patent Abuse
CSRxP’s Solutions
Drug prices in the United States are out of control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. Rising prescription drug prices threaten the affordability of our health care system, the long-term health of our nation and the vitality of our entire economy. Public opinion research finds as many as one-in-three Americans experience financial difficulty, either as a patient themselves or through a family member, affording prescription drugs. CSRxP has developed market-based solutions to restore a functioning market and lower prices for patients by increasing list price transparency, promoting competition and actual innovation and focusing on better value for patients, not better value for pharmaceutical companies.
News & Updates
Oct 14, 2026
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Big Pharma Giant Beats Earnings, Projects $100 Billion in Annual Sales Following Price…
Sep 30, 2026
DOSE OF REALITY: JAMA STUDY FINDS DRUG PATENT PORTFOLIOS ON SMALL MOLECULE DRUGS HAVE MORE THAN TRIPLED, DELAYING GENERIC COMPETITION
New Analysis Shows Brand Name Drug Companies Increasingly Rely On Follow-On Patents To…
Sep 30, 2026
DOSE OF REALITY: AARP ANALYSIS EXAMINES PATENT ABUSE ON BRAND NAME INHALER THAT KEPT PRICES HIGH FOR PATIENTS
Report Details How Tactics Like Patent Thicketing and Product Hopping Delayed…
Featured Content
Jul 30, 2026
CSRxP: ETHIC Act & Skinny Labels, Big Savings Act
Two bipartisan solutions — the ETHIC Act and Skinny Labels, Big Savings Act… Read More
Jul 27, 2026
CSRxP: Margin Analysis
SEC filings show that brand name pharmaceutical manufacturers’ profit… Read More
Jul 21, 2026
CSRxP: Senate HELP Fact Sheet
Bipartisan, Market-Based Solution Would Streamline Drug Approval Process and… Read More
Jul 20, 2026
CSRxP: E&C Markup Fact Sheet
How Congress Can Lower Drug Prices, Boost Competition Bipartisan,… Read More
Resources
Videos
Watch and learn about Big Pharma’s price-gouging techniques that are the cause of out-of-control drug prices.
Fact Sheets
Get the facts on Big Pharma’s anti-competitive tactics, like price-gouging and patent abuse that keeps drug prices high.
Infographics
Learn about how Big Pharma is driving the Rx drug pricing crisis with our infographics.
Polling
See recent surveys on American voters’ opinions on Big Pharma’s blame game and out-of-control drug pricing.
JOIN THE FIGHT
Join us in telling lawmakers: It’s time to hold Big Pharma accountable and lower Rx drug prices.